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Objective: Proximal attachment site complications continue to occur after endovascular repair of abdominal aortic an-
eurysms (EVAR), speciﬁcally type Ia endoleak and endograft migration. EndoAnchors (Aptus Endosystems, Sunnyvale,
Calif) were designed to enhance endograft proximal ﬁxation and sealing, and the current study was undertaken to
evaluate the potential beneﬁt of this treatment.
Methods: During the 23-month period ending in December 2013, 319 subjects were enrolled at 43 sites in the United
States and Europe. EndoAnchors were implanted in 242 patients (75.9%) at the time of an initial EVAR procedure
(primary arm) and in 77 patients with an existing endograft and proximal aortic neck complications (revision arm).
Technical success was deﬁned as deployment of the desired number of EndoAnchors, adequate penetration of the vessel
wall, and absence of EndoAnchor fracture. Procedural success was deﬁned as technical success without a type Ia endoleak
at completion angiography. Values are expressed as mean 6 standard deviation and interquartile range.
Results: The 238 male (74.6%) and 81 female (25.4%) subjects had a mean age of 74.16 8.2 years. Aneurysms averaged 58 6
13 (51-63) mm in diameter at the time of EndoAnchor implantation (core laboratory measurements). The proximal aortic neck
averaged 166 13 (7-23) mm in length (42.7% <10mm and 42.7% conical) and 276 4mm (25-30mm) in diameter; infrarenal
neck angulation was 24 6 15 (13-34) degrees. The number of EndoAnchors deployed was 5.8 6 2.1 (4-7). Technical success
was achieved in 303 patients (95.0%) and procedural success in 279 patients (87.5%), 217 of 240 (89.7%) and 62 of 77 (80.5%)
in the primary and revision arms, respectively. There were 29 residual type Ia endoleaks (9.1%) at the end of the procedure.
During mean follow-up of 9.3 6 4.7 months, 301 patients (94.4%) were free from secondary procedures. Among the 18
secondary procedures, eight were performed for residual type Ia endoleaks and the others were unrelated to EndoAnchors.
There were no open surgical conversions, there were no aneurysm-related deaths, and no aneurysm ruptured during follow-up.
Conclusions: Use of EndoAnchors to treat existing and acute type Ia endoleaks and endograft migration was successful in
most cases. Prophylactic use of EndoAnchors in patients with hostile aortic neck anatomy appears promising, but
deﬁnitive conclusions must await longer term follow-up data. (J Vasc Surg 2014;60:885-92.)the Division of Vascular Surgery and Endovascular Therapy, University
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886 Jordan et al October 2014Endoleaks and endograft migration continue to occur
after endovascular aortic aneurysm repair (EVAR), particu-
larly in patients with hostile proximal aortic neck anat-
omy.1-4 Imported devices and skills have prompted
clinicians to treat more challenging cases, for instance,
those with a short, conically shaped, large-diameter, or
highly angulated aortic neck conﬁguration.5 Improving
the performance of devices in the setting of a challenging
proximal aortic neck attains relevance with respect to two
concerns. First, the presence of challenging proximal neck
anatomy increases the risk of high-pressure endoleaks,
endograft migration, secondary procedures, and potential
for late aneurysm rupture. Second, hostile aortic neck anat-
omy remains a barrier to the widespread use of EVAR for
infrarenal aneurysms. Even with current devices, many pa-
tients do not meet the proximal aortic neck eligibility
criteria for such endografts.6
The Heli-FX EndoAnchor System (Aptus Endosys-
tems, Sunnyvale, Calif) was designed to improve ﬁxation
and sealing of an endograft within the proximal aortic
neck.7 Securing the endograft to the aortic wall with
EndoAnchors mimics a surgically sutured anastomosis.8
Whereas the current data are anecdotal, EndoAnchors
have the potential to diminish the risk of proximal aortic
neck complications when challenging neck anatomy is
encountered at the time of an initial endograft implanta-
tion.9,10 As well, EndoAnchors hold potential for treatment
of endoleaks and migration when these complications are
discovered in a previously placed endograft. The demonstra-
tion of clinical beneﬁt after the prophylactic and therapeutic
use of EndoAnchors will increase eligibility for EVAR to
those with more complex aortic neck anatomy, improve
the durability of endovascular repair through a more robust
attachment between the endograft and the aorta, and facil-
itate an endovascular solution when type Ia endoleaks and
migration are detected.
METHODS
The Aneurysm Treatment using the Heli-FX Aortic
Securement System Global Registry (ANCHOR) study is
a single-arm, prospective, multicenter, multinational study
of the real-world use of the currently available Heli-FX sys-
tem with EndoAnchors in patients undergoing or who
have undergone EVAR for infrarenal abdominal aortic an-
eurysms (AAAs). Participating investigators are listed in the
Appendix, online only.
Study design. The study was registered on Clinical
Trials.gov onFebruary 9, 2012 (NCT01534819). Informed
consent was obtained of every patient, and the study was
conducted according to the Declaration of Helsinki, appli-
cable sections of ISO 14155,MEDDEV 2.12-2, and the In-
ternational Conference on Harmonization Good Clinical
Practice guidelines. Eligible patients included those with
asymptomatic, symptomatic, or ruptured AAA; adequate
iliofemoral access for accommodation of a 16F sheath; life
expectancy of 1 year or more; and no history of allergy to
the metallic components of the device. Suitable endografts
included the Zenith (Cook, Bloomington, Ind); theExcluder (W. L. Gore, Flagstaff, Ariz); and the AneuRx,
Talent, or Endurant devices (Medtronic Vascular, Santa
Rosa, Calif). Exclusion criteria included prior EndoAnchor
implantation, known bleeding diathesis, infection, and
signiﬁcant proximal aortic neck thrombus or calcium that
would preclude adequate EndoAnchor penetration into
the aortic wall. Consent could be obtained before Endo-
Anchor implantation or within 30 days after EndoAnchor
implantation to include those patients with unplanned
use of the device. To exclude selection bias, investigators
were asked to enroll patients before the acquisition of
the ﬁrst postoperative imaging study (there were two pro-
tocol deviations from subjects enrolled beyond the 30-day
window).
The primary arm comprised those patients with
EndoAnchor implantation at the same procedure as the
initial EVAR procedure. Patients in the primary arm were
treated for prophylaxis of endoleak or migration when,
in the opinion of the investigator, the anatomy put the pa-
tient at risk for future proximal aortic neck complications.
Patients were also included in the primary arm when
EndoAnchors were used to treat a type Ia endoleak evident
at the time of an initial EVAR procedure. The revision arm
included patients who had prior EVAR and presented with
type Ia endoleak or endograft migration. Aortic extender
cuffs were usually employed in this group when the original
endograft was not adequately juxtaposed to the lowest
renal artery, from either migration or misdeployment.
Study device. The Aptus Heli-FX EndoAnchor Sys-
tem consists of the Heli-FX Guide, EndoAnchors, and the
Heli-FX Applier (Fig 1). The system is intended to provide
ﬁxation of an endograft to the aortic wall. The Heli-FX
Applier is passed through the lumen of the Heli-FX
Guide, and each EndoAnchor (4.5 mm in length, 3 mm
in diameter) is implanted in a two-stage process to allow
retraction of the EndoAnchor and repositioning before
ﬁnal deployment (Fig 2). The use of the device has been
described in previous publications.7-13
End points and deﬁnitions. The index procedure was
deﬁned as the initial procedure in which EndoAnchors
were implanted. Patients in the primary arm were those
in whom the index procedure was concurrent with the
initial endograft implantation. Patients in the revision arm
were those in whom the index procedure was remote
from prior EVAR. A proximal aortic neck was determined
to be conical in conﬁguration if its diameter increased more
than 10% beyond the immediate infrarenal diameter within
the ﬁrst 10 mm of the lowest main renal artery. Signiﬁcant
mural thrombus or calcium was deﬁned if its average thick-
ness was >1 mm. Reporting of reinterventions and adverse
events followed the Society for Vascular Surgery reporting
standards for adverse events after medical device use and
for endovascular aneurysm repair.14,15 Primary effective-
ness and primary safety end points were prespeciﬁed in the
Study Protocol. The primary efﬁcacy end point required
successful implantation of the minimum number of
EndoAnchors as deﬁned in the Instructions for Use (IFU)
with respect to the diameter of the aortic neck and freedom
Fig 2. Deployment of EndoAnchors through endograft and into aortic wall. (Image from Aptus Endosystems with
permission.)
Fig 1. The Aptus Heli-FX device. A, Delivery system. B, EndoAnchor. (Image from Aptus Endosystems with
permission.)
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12 months. The primary safety end point was a com-
posite deﬁned as freedom from serious adverse device-
related events or procedure-related adverse events
during 12-months, excluding those events solely attrib-
utable to the endograft or the endograft implantation
procedure but including aneurysm-related mortality.
Technical success was deﬁned as deployment of the
desired number of EndoAnchors with adequate pene-
tration of the vessel wall and without EndoAnchor
fracture and with uneventful removal of the Heli-FX
Guide. Procedural success was deﬁned as technicalsuccess without a type Ia endoleak at completion angi-
ography. Details of the procedure and the hospitalization
were recorded; these included total procedure time, time
to implant EndoAnchors, duration of ﬂuoroscopy, and
length of intensive care unit stay and hospital stay. Sec-
ondary end points were not prespeciﬁed but included the
frequency of endoleak (all types), migration (>10 mm),
all-cause mortality, and secondary procedures.
Imaging studies. Follow-up was not protocol driven
but was performed according to each investigator’s stan-
dard of care. Societal guidelines were recommended for
computed tomography (CT) imaging with and without
Table I. Baseline characteristics
Primary arm (n ¼ 242) Revision arm (n ¼ 77) All (N ¼ 319)
Age, years 73.8 6 8.3 77.4 6 7.1 74.1 6 8.2
Male/female 74.4%/25.6% 75%/25% 74.6%/25.4%
Height, cm 172.8 6 15.3 171.4 6 15.5 172.5 6 15.3
Weight, kg 83.3 6 19.2 84.1 6 19.5 83.5 6 19.3
Comorbidities, n/N (%)
Hypertension 197/242 (81.4) 66/77 (85.7) 263/319 (82.4)
Hyperlipidemia 169/242 (69.8) 58/77 (75.3) 227/319 (71.2)
Diabetes 46/241 (19.1) 15/77 (19.5) 61/318 (19.2)
Cardiac 144/241 (59.8) 44/77 (57.1) 188/318 (59.1)
Pulmonary 77/241 (32.0) 23/77 (29.9) 100/318 (31.4)
Renal 50/241 (20.7) 17/76 (22.4) 67/317 (21.1)
Cerebrovascular/neurologic 36/242 (14.9) 10/75 (13.3) 46/317 (14.5)
Bleeding disorder 3/241 (1.2) 1/77 (1.3) 4/318 (1.3)
Gastrointestinal 79/241 (32.8) 18/77 (23.4) 97/318 (30.5)
Genitourinary 58/241 (24.1) 12/77 (15.6) 70/318 (22.0)
Vascular 112/241 (46.5) 26/77 (33.8) 138/318 (43.4)
Thoracic aneurysm 16/241 (6.6) 2/77 (2.6) 18/318 (5.7)
Denominators are smaller than group size because of missing values.
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duplex ultrasonography at 30 days and 12 months and
annually thereafter. Independent core laboratory analyses
(Syntactx, New York, NY) were performed on non-
contrast-enhanced and contrast-enhanced CT imaging
studies that were available at the time of data lock on
December 13, 2013. Centerline reformatting and seg-
mentation of CT data sets were performed with iNtuition
imaging software (TeraRecon, Foster City, Calif). The
proximal aortic neck length was calculated as the length at
which the aortic diameter remained no more than 10%
greater than the immediate infrarenal diameter. Infrarenal
aortic neck angulation was deﬁned by three centerline
points: 20 mm proximal to the lowest renal artery, at the
lowest renal artery, and 40 mm distal to the lowest renal
artery. Aortic neck calcium and thrombus content was
measured and expressed in degrees of circumference where
the involvement exceeded 1.0 mm.
Data management and statistics. An electronic data
capture system was used (iMedNet, Minnetonka, Minn).
Each electronic case report form was veriﬁed and electron-
ically signed by the investigators. All elements of each case
report form were remotely monitored by independent re-
viewers (Syntactx). All safety end points were evaluated
by an independent Medical Monitor in both individual list-
ings and summary table format. The Medical Monitor
identiﬁed any unanticipated adverse device effects that by
virtue of severity or incidence, individually or in the aggre-
gate, were not previously expected.15
No sample size calculation was performed because of the
observational study design that was not hypothesis driven.
Continuous variables are expressed as mean and standard de-
viation, median and interquartile range (IQR). Dichotomous
end points were calculated as a numerator, deﬁned as the
number of subjects triggering the end point, divided by a de-
nominator, deﬁned as the number of subjects available for
analysis. Imputation of missing data was not performed,
nor was any interim analysis planned except for publicationor safety and regulatory purposes. P values were considered
to be signiﬁcant when the two-tailed a was less than .05.
RESULTS
During the period between February 2012 and
December 2013, 319 patients from 43 sites in the United
States, The Netherlands, Germany, Italy, and the United
Kingdom were enrolled in ANCHOR. Among these, 242
patients (75.8%) were primary cases and 77 (24.1%) were
revisions. The number of subjects enrolled per site ranged
from 1 to 59 (average, 7.4 6 10.5).
Baseline patient characteristics. Patient demo-
graphics and risk factors are listed in Table I. Aneurysms
were asymptomatic in 87.8% and symptomatic in 12.2%.
Aneurysms were intact in 99.0% and ruptured in 1.0%. The
American Society of Anesthesiologists physical status was 1
in three patients (0.9%), 2 in 29 patients (8.9%), 3 in 228
patients (71.5%), and 4 in 59 patients (18.5%). Core lab-
oratory analysis of baseline anatomic characteristics is
summarized in Table II.
Index procedure. Details of the index procedure are
displayed in Table III. The principal indications for
EndoAnchor use in the primary arm were concern for
future type Ia endoleak or migration in 186 cases with
hostile proximal aortic neck anatomy (76.9%), treatment of
a type Ia endoleak after endograft deployment in 52 cases
(21.5%), and treatment of misdeployed endografts in four
cases (1.7%). The principal indications for EndoAnchor use
in the revision arm were treatment of a type Ia endoleak in
45 cases (58%), treatment of endograft migration with type
Ia endoleak in 21 cases (27%), and treatment of migration
without type Ia endoleak in 11 cases (14%). The endografts
in the primary and revision arms are displayed in Table IV.
The index procedure was performed in an operating
room setting in 246 patients (77.1%), in an endovascular
suite in 42 patients (13.2%), and in a catheterization labora-
tory in 31 patients (9.7%). The procedurewas performed un-
der general anesthesia in 283 patients (88.7%), regional
Table II. Anatomic characteristics (core laboratory analysis)
Primary arm Revision arm All
Maximum aneurysm diameter, mm 56 6 11 (50-60) 65 6 13 (58-75) 58 6 13 (51-63)
Aortic neck length, mm 17 6 13 (7-24) 15 6 12 (6-20) 16 6 13 (7-23)
5 mm or less 14.1% 23.3% 16.7%
10 mm or less 41.7% 46.5% 42.7%
15 mm or less 58.3% 60.5% 58.8%
Aortic neck diameter, mm 26 6 4 (23-28) 29 6 5 (26-32) 27 6 4 (25-30)
Suprarenal angulation, degrees 16 6 12 (8-21) 12 6 10 (6-17) 15 6 11 (7-20)
Infrarenal angulation, degrees 25 6 15 (13-35) 24 6 16 (12-32) 24 6 15 (13-34)
Thrombus in neck, % patients 36.6% 21.4% 33.2%
>90 degrees of circumference 12.7% 23.2% 10.0%
61-90 degrees of circumference 1.2% 2.4% 0.9%
31-60 degrees of circumference 0.7% 2.3% 0.5%
Calcium in neck, % patients 48.1% 11.6% 40.2%
>90 degrees of circumference 1.3% 0% 1.0%
61-90 degrees of circumference 2.5% 0% 2.0%
31-60 degrees of circumference 5.1% 4.7% 5.0%
Conical proximal aortic neck 41.7% 46.5% 42.7%
Data are presented as frequencies or mean 6 standard deviation (interquartile range).
Table III. Index procedure data
Primary (n ¼ 242) Revisions (n ¼ 77) All (N ¼ 319)
Percutaneous access 22.9% 27.0% 23.9%
Anesthesia
General 88.8% 88.3% 88.7%
Epidural 1.7% 1.3% 1.6%
Spinal 1.9% 2.1% 1.3%
Local 9.1% 7.4% 7.8%
Number of EndoAnchorsa 5.5 6 1.8 (4-6) 6.8 6 2.6 (5-9) 5.8 6 2.1 (4-7)
Duration of procedure,a minutes 138 6 71 (90-172) 143 6 89 (90-162) 138 6 76 (90-170)
Duration of EndoAnchor implantation,a minutes 18 6 21 (7-20) 21 6 22 (6-26) 19 6 21 (7-24)
Technical successb 96.3% 90.9% 95.0%
Procedural successb 89.7% 80.5% 87.5%
aMean 6 standard deviation (interquartile range).
bTechnical success is deﬁned as deployment of the desired number of EndoAnchors with adequate penetration of the vessel wall and without EndoAnchor
fracture. Procedural success is deﬁned as technical success without a type Ia endoleak at completion angiography.
Table IV. Endografts in the primary and revision arms
Primary arm
(n ¼ 242),
No. (%)
Revision arm
(n ¼ 77),
No. (%)
All
(N ¼ 319),
No. (%)
Gore Excluder 86 (35.5) 16 (20.8) 102 (32.0)
Cook Zenith 40 (16.5) 11 (14.3) 51 (16.0)
Medtronic Endurant 112 (46.3) 10 (13.0) 122 (38.2)
Medtronic AneuRx 0 18 (23.4) 18 (5.6)
Medtronic Talent 0 14 (18.2) 14 (4.4)
Other 4 (1.7) 8 (10.4) 12 (3.8)
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patients (7.8%). Access was percutaneous in 23.9% and by
cutdown in 76.1%. The total duration of the procedures
was 139 6 76 minutes, of which 19 6 17 minutes was
devoted to introduction and deployment of EndoAnchors.
The mean total ﬂuoroscopic time was 30 6 14 minutes.
Admission to an intensive care unit was required in 32.8%
of patients, and the mean intensive care unit stay was 1.9 6
1.5 days in those who were admitted. The mean hospital
stay was 3.5 6 6.0 days (median, 2 days; IRQ, 1-4 days).
The median number of EndoAnchors deployed was
ﬁve in the primary arm (IQR, 4-6) and seven in the revision
group (IQR, 5-8). EndoAnchor deployment was techni-
cally successful in 304 patients (95.3%). EndoAnchor pene-
tration of the aortic wall was deemed inadequate by the
investigator in 15 cases (4.7%), as assessed at the index pro-
cedure. Among these, inadequate penetration resulted
from EndoAnchor fracture in two patients (0.6%), inten-
tional deployment between two endograft components
distal to the proximal neck in two patients (0.6%), and
inability to position the guide in one patient (0.3%). Eachof the EndoAnchor fractures was thought to be a result
of torquing of the guide before complete EndoAnchor
release.
Aortic extension cuffs were used in 24 patients in the
primary arm, four of which were placed after unsatisfactory
endograft deployment distally in the aortic neck. Bare
metal aortic stents (all Palmaz) were deployed in four pa-
tients in the primary arm, each for residual type Ia
Table V. Early outcome by indication for EndoAnchor use in all patients and in the primary and revision arms
Patients, No.
Technical
success,a No. (%)
Procedural
success,b No. (%)
No evidence of type
Ia leak at completion
angiography, No. (%)
All 319 303 (95.0) 279 (87.5) 290 (90.9)
Primary arm 242 233 (96.3) 217 (89.7) 223 (92.1)
Prophylaxis for hostile neck 186 180 (96.8) 172 (92.5) 177 (95.2)
Treatment of type Ia endoleak 52 51 (98.1) 43 (82.7) 43 (82.7)
Treatment of distal deployment 4 2 (50.0) 2 (50) 3 (75.0)
Revision arm 79 70 (90.9) 62 (80.5) 67 (87.0)
Treatment of type Ia endoleak 45 43 (95.6) 35 (77.8) 36 (80.0)
Treatment of migration 11 8 (72.7) 8 (72.7) 11 (100)
Treatment of endoleak and migration 21 19 (90.5) 19 (90.5) 20 (95.2)
aTechnical success is deﬁned as deployment of the desired number of EndoAnchors with adequate penetration of the vessel wall and without EndoAnchor
fracture.
bProcedural success is deﬁned as technical success without a type Ia endoleak at completion angiography.
Table VI. Secondary procedures
Secondary procedure Primary arm (n ¼ 242), No. (%) Revision arm (n ¼ 77), No. (%) All (N ¼ 319), No. (%)
Open surgical conversion 0 0 0
Repair of type Ia endoleak 1 (0.4) 7 (9.1) 8 (2.5)
Treatment of type II endoleak 1 (0.4) 4 (5.2) 5 (1.6)
Treatment of migration 0 0 0
Treatment of graft limb kinking 1 (0.4) 1 (1.3) 2 (0.6)
Treatment of graft limb occlusion 2 (0.8) 1 (1.3) 3 (0.9)
Treatment of access vessel injury 1 (0.4) 0 1 (0.3)
Lower extremity revascularization 2 (0.8) 1 (1.3) 3 (0.9)
Total secondary proceduresa 7 (2.9) 11 (14.3) 18 (5.6)
Total patients with secondary procedures 7 (2.9) 7 (9.1) 14 (4.4)
aSome secondary procedures addressed more than one indication.
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these remained after stent placement. Aortic extender cuffs
were used in 50 patients in the revision arm: nine in pa-
tients with endograft migration, 17 in patients with type
Ia endoleak and migration, and 24 in patients with type
Ia endoleak alone. Bare metal aortic stents were placed in
three patients in the revision arm to treat residual type Ia
endoleaks after EndoAnchor deployment. Among these,
two were Palmaz stents (Cordis Endovascular, Warren,
NJ), and one was an AndraStent (Andramed, Reutlingen,
Germany). Endoleaks remained in two of these three cases.
Technical success was achieved in 303 patients (95.0%),
233 (96.3%) of the patients in the primary arm and 70
(90.9%) of the patients in the revision arm. Procedural suc-
cess was accomplished in 279 patients (87.5%) overall, 217
of 242 in primary cases (89.7%) and 62 of 77 in revisions
(80.5%). Results by indication for EndoAnchor use are listed
in Table V. There were 29 residual type Ia endoleaks (9.1%)
at the end of the procedure, four of which occurred in the 15
patients with technically unsuccessful EndoAnchor deploy-
ment. There were no instances of EndoAnchors causing
an endoleak. In one patient in whom EndoAnchor implan-
tation was attempted before completion of endograft
deployment, an EndoAnchor entrapped the proximal
release wire of an Excluder C3 delivery system (W. L.
Gore) and resulted in the inability to remove the endograftdelivery device. Additional maneuvers were required to
remove the delivery device, but open surgical conversion
was not necessary.
Follow-up. During a mean follow-up period of 9.3 6
4.7 months, no patient developed a new type Ia endoleak or
endograft migration after the index procedure. A total of 18
secondary procedures were necessary in 14 patients (4.4%),
seven (2.9%) in the primary arm and 11 (14.3%) in the
revision arm (Table VI). Secondary procedures were aneu-
rysm related in four of the primary cases (1.7%) and in 10 of
the revisions (13%). Secondary procedures were performed
for residual type Ia endoleaks in one patient (0.4%) in the
primary arm and in seven patients (9.1%) in the revision arm.
The frequency of secondary procedures was greatest in the
early postprocedure period; 8 (44.4%) occurred within
30 days, 5 (29.4%) between 31 and 90 days, and the
remaining 5 (29.4%) more than 180 days after the index
procedure. Secondary procedures performed within the
30 days of the index procedure were done to treat residual
type Ia endoleaks (4) or leg ischemia (4), whereas pro-
cedures beyond 90 days were most commonly performed to
treat type II endoleaks (4).
Theprimary safety endpointwas achieved in294patients
(92.2%) overall and in 226 patients (93.4%) in the primary
arm and in 68 patients (88%) in the revision arm. No patient
experienced an unanticipated adverse device effect. There
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none of which was aneurysm related or device related.
DISCUSSION
The proximal aortic neck remains an important area of
failure after endovascular treatment of AAAs, particularly
when the aortic neck is short, highly angulated, or conical.
Even with currently available endografts, a large number of
patients with AAA will fall outside the device IFU,6 and
approximately one ﬁfth are entirely unsuitable for standard
endovascular repair because of neck anatomy requiring the
endograft to cross the renal ostia to achieve sealing.16 The
IFU of most currently marketed endografts limit the
intended use of the devices to those patients with a proximal
aortic neck of at least 10 mm and in most cases 15 mm in
length. Even the Cook Zenith fenestrated endograft IFU
suggest that the proximal neck length be at least 4 mm in
length. Further, most current endografts are limited to prox-
imal aortic neck angulation of less than 60 degrees.
The term hostile neck has been applied to a short, angu-
lated, or conically shaped proximal aortic neck or when the
neck contains abundant thrombus or calcium, and the results
of EVAR are inferior when it is employed in such cases.1,17-21
A meta-analysis of seven studies by Antoniou et al22
compared early and late outcomes ofEVARperformed in pa-
tients with hostile vs friendly aortic neck anatomy. The
requirement for adjunctive procedures was more frequent
in the presence of a challenging proximal aortic neck anat-
omy. Type I endoleaks were almost ﬁve times more likely
at 1 year after endograft implantation in patients with hostile
proximal aortic neck anatomy (P¼ .010). As well, the risk of
aneurysm-related mortality was ninefold higher in patients
with hostile neck anatomy (P ¼ .013).
Recognizing these limitations, EndoAnchors were
designed as an adjunct to endovascular aneurysm repair
to enhance ﬁxation and sealing at the attachment site be-
tween an endograft and the aortic wall. An in vitro study
documented an increase in the force required to displace
an endograft from silicone tubes and human cadaveric
aortas when EndoAnchors were used.8 EndoAnchors do
not address a thrombus- or calcium-laden aortic neck and
are contraindicated when mural thrombus or calcium
would prohibit the penetration of the EndoAnchor into
the aortic wall at the site of intended deployment. Fixation
and sealing, however, can be improved in short, angulated,
or conical aortic necks.7,9,23 The ANCHOR trial was
designed to evaluate the performance of the Heli-FX Sys-
tem in two groups of patients with AAA, those undergoing
initial implantation of an endograft (primary arm) and
those in whom a previously placed endograft developed
proximal neck complications (revision arm). The primary
arm comprised those patients undergoing primary repair
with a commercially available endograft. EndoAnchors
were used in this group in two different clinical scenarios:
prophylactically, when the treating physician believed that
long-term endograft ﬁxation and sealing would be compro-
mised by challenging proximal aortic neck anatomy; and
therapeutically, when completion angiography revealed atype Ia endoleak. The revision armwasmore homogeneous,
comprising patients who underwent EVAR in the past and
presented with type Ia endoleak or endograft migration
remote from the initial endograft implantation procedure.
At times, EndoAnchors were used outside of the device
IFU, but these patients were still included in the overall
data analysis, albeit identiﬁed as protocol deviations.
The ANCHOR cohort comprised patients with more
challenging aortic anatomy than is characteristically
encountered in the overall population of patients undergo-
ing EVAR. In comparison to a large data set of preopera-
tive anatomic baseline characteristics in EVAR patients
reported by Schanzer et al,24 the ANCHOR primary arm
had, on average, shorter length (17 vs 21 mm) and larger
diameter (26 vs 23 mm) proximal aortic necks. As well,
aortic neck length of less than 10 mm was more common
in the ANCHOR primary patients (42% vs 24%), and necks
were more often conical in conﬁguration (42% vs 32%).
The anatomic variance between the ANCHOR revision
arm and the Schanzer series is even more striking, a not un-
expected ﬁnding in view of the selection differences be-
tween the two study populations.
Despite the challenging proximal aortic neck anatomy
in the ANCHOR patients, midterm outcome was excel-
lent. Prophylactic EndoAnchor implantation was associated
with procedural success in approximately 90% and 80% of
the primary and revision arms, respectively, and no patient
developed new type Ia endoleaks or endograft migration in
follow-up. This observation, however, must be taken in the
context of the limited follow-up currently available, the
limited number of cases performed at some of the investi-
gational sites, and the nonhomogeneity of treatment para-
digms from center to center. The frequency of such
complications increases with longer length of follow-up.
Perhaps more compelling are the results in therapeutically
treated patients who presented with proximal aortic neck
complications either at the time of endograft implantation
or remote from the initial procedure. EndoAnchor use was
associated with resolution of type Ia endoleaks in approxi-
mately 80% of patients treated, and once resolved, no
endoleak reappeared on follow-up imaging studies. It is
axiomatic that patients presenting with endograft migra-
tion will require the use of an aortic extension endopros-
thesis in addition to EndoAnchors. The outcome of
patients who received both EndoAnchors and aortic exten-
sions cannot be parsed between the effects of the two de-
vices. However, each investigator makes the decision
about using both modalities, considering that the primary
endograft has already exhibited failure because of proximal
aortic neck problems. In other patients in whom the
endograft was deployed well below the level of the renal ar-
teries, an aortic extension cuff might be used alone, and
the patient would not be included in the registry. These ex-
amples illustrate the principle that the management of
proximal neck complications often requires the use of mul-
tiple modalities, each of which should be in the armamen-
tarium of the endovascular surgeon.25 Even with multiple
modalities, however, failures may occur. Although an
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causes include deployment of an inadequate number of
EndoAnchors or deployment nonuniformly over the cir-
cumstances of the aortic neck; incomplete penetration of
EndoAnchors into the aortic wall due to thrombus, calcium,
or misdeployment; and failure from severe luminal irregular-
ities within the neck that preclude endograft apposition.
CONCLUSIONS
The results of the ANCHOR study suggest that
EndoAnchors are of utility to secure an endograft in pa-
tients with challenging proximal aortic neck anatomy.
Considering that there have been no unanticipated serious
device events, we conclude that the device is safe to use in
this population. Clinical beneﬁts unambiguously accrue to
the group of patients with frank type Ia endoleak or migra-
tion, with resolution of the problem in the majority of
cases. ANCHOR also enrolled patients with prophylactic
implantation of EndoAnchors at the time of initial EVAR
in patients with unfavorable proximal neck anatomy.
Whereas the conﬁrmation of clinical beneﬁt in prophylacti-
cally treated patients can be conclusively established only
with a randomized comparison of patients treated with
and without EndoAnchors, the midterm observations of
ANCHOR appear encouraging.AUTHOR CONTRIBUTIONS
Conception and design: WJ, KO, JV
Analysis and interpretation: WJ, KO
Data collection: WJ, MM, DV, WM, FA, JJ, KO, JV
Writing the article: WJ, KO
Critical revision of the article: WJ, MM, DV, WM, FA, JJ,
KO, JV
Final approval of the article: WJ, MM, DV, WM, FA, JJ,
KO, JV
Statistical analysis: KO
Obtained funding: Not applicable
Overall responsibility: WJREFERENCES
1. Aburahma AF, Campbell JE, Mousa AY, Hass SM, Stone PA, Jain A,
et al. Clinical outcomes for hostile versus favorable aortic neck anatomy
in endovascular aortic aneurysm repair using modular devices. J Vasc
Surg 2011;54:13-21.
2. Hobo R, Kievit J, Leurs LJ, Buth J. Inﬂuence of severe infrarenal aortic
neck angulation on complications at the proximal neck following
endovascular AAA repair: a EUROSTAR study. J Endovasc Ther
2007;14:1-11.
3. Waasdorp EJ, de Vries JP, Hobo R, Leurs LJ, Buth J, Moll FL.
Aneurysm diameter and proximal aortic neck diameter inﬂuence clinical
outcome of endovascular abdominal aortic repair: a 4-year EURO-
STAR experience. AnnVasc Surg 2005;19:755-61.
4. Sternbergh WC 3rd, Carter G, York JW, Yoselevitz M, Money SR.
Aortic neck angulation predicts adverse outcome with endovascular
abdominal aortic aneurysm repair. J Vasc Surg 2002;35:482-6.
5. Verhagen HJ, Torsello G, de Vries JP, Cuypers PH, Van
Herwaarden JA, Florek HJ, et al. Endurant stent-graft system: pre-
liminary report on an innovative treatment for challenging abdominal
aortic aneurysm. J Cardiovasc Surg (Torino) 2009;50:153-8.6. Sweet MP, Fillinger MF, Morrison TM, Abel D. The inﬂuence of
gender and aortic aneurysm size on eligibility for endovascular
abdominal aortic aneurysm repair. J Vasc Surg 2011;54:931-7.
7. Deaton DH. Improving proximal ﬁxation and seal with the HeliFx
Aortic EndoAnchor. Semin Vasc Surg 2012;25:187-92.
8. Melas N, Perdikides T, Saratzis A, Saratzis N, Kiskinis D, Deaton DH.
Helical EndoStaples enhance endograft ﬁxation in an experimental
model using human cadaveric aortas. J Vasc Surg 2012;55:1726-33.
9. Perdikides T, Melas N, Lagios K, Saratzis A, Siafakas A, Bountouris I, et al.
Primary endoanchoring in the endovascular repair of abdominal aortic an-
eurysms with an unfavorable neck. J Endovasc Ther 2012;19:707-15.
10. de Vries JP, Schrijver AM, Van den Heuvel DA, Vos JA. Use of
endostaples to secure migrated endografts and proximal cuffs after
failed endovascular abdominal aortic aneurysm repair. J Vasc Surg
2011;54:1792-4.
11. de Vries JP. The proximal neck: the remaining barrier to a complex
EVAR world. Semin Vasc Surg 2012;25:182-6.
12. Deaton DH, Mehta M, Kasirajan K, Chaikof E, Farber M,
Glickman MH, et al. The phase I multicenter trial (STAPLE-1) of the
Aptus endovascular repair system: results at 6 months and 1 year. J Vasc
Surg 2009;49:851-7.
13. Mehta M, Henretta J, Glickman M, Deaton D, Naslund TC, Gray B,
et al. Outcome of the pivotal study of the Aptus endovascular
abdominal aortic aneurysms repair system. J Vasc Surg 2014;60:275-85.
14. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
15. Ouriel K, Fowl RJ, Davies MG, Forbes TL, Gambhir RP, Morales JP,
et al. Reporting standards for adverse events after medical device use in
the peripheral vascular system. J Vasc Surg 2013;58:776-86.
16. Malina M, Resch T, Sonesson B. EVAR and complex anatomy: an update
on fenestrated and branched stent grafts. Scand J Surg 2008;97:195-204.
17. Dillavou ED, Muluk SC, Rhee RY, Tzeng E, Woody JD, Gupta N,
et al. Does hostile neck anatomy preclude successful endovascular
aortic aneurysm repair? J Vasc Surg 2003;38:657-63.
18. Choke E, Munneke G, Morgan R, Belli AM, Loftus I, McFarland R,
et al. Outcomes of endovascular abdominal aortic aneurysm repair in
patients with hostile neck anatomy. Cardiovasc Intervent Radiol
2006;29:1435-41.
19. Cox DE, Jacobs DL, Motaganahalli RL, Wittgen CM, Peterson GJ.
Outcomes of endovascular AAA repair in patients with hostile neck
anatomy using adjunctive balloon-expandable stents. Vasc Endovas-
cular Surg 2006;40:35-40.
20. Georgiadis GS, Trellopoulos G, Antoniou GA, Gallis K,
Nikolopoulos ES, Kapoulas KC, et al. Early results of the Endurant
endograft system in patients with friendly and hostile infrarenal
abdominal aortic aneurysm anatomy. J Vasc Surg 2011;54:616-27.
21. Hoshina K, Kato M, Hosaka A, Miyahara T, Mikuriya A, Ohkubo N,
et al. Middle-term results of endovascular aneurysm repair in Japan: does
intraoperative endovascular management against the hostile aneurysmal
neck prevent the proximal type I endoleak? Int Angiol 2011;30:467-73.
22. Antoniou GA, Georgiadis GS, Antoniou SA, Kuhan G, Murray D.
A meta-analysis of outcomes of endovascular abdominal aortic aneu-
rysm repair in patients with hostile and friendly neck anatomy. J Vasc
Surg 2013;57:527-38.
23. Avci M, Vos JA, Kolvenbach RR, Verhoeven EL, Perdikides T,
Resch TA, et al. The use of endoanchors in repair EVAR cases to
improve proximal endograft ﬁxation. J Cardiovasc Surg (Torino)
2012;53:419-26.
24. Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH,
Goldberg RJ, et al. Predictors of abdominal aortic aneurysm sac
enlargement after endovascular repair. Circulation 2011;123:2848-55.
25. Rajani RR, Arthurs ZM, Srivastava SD, Lyden SP, Clair DG,
Eagleton MJ. Repairing immediate proximal endoleaks during
abdominal aortic aneurysm repair. J Vasc Surg 2011;53:1174-7.
Submitted Jan 15, 2014; accepted Apr 22, 2014.
Additional material for this article may be found online at
www.jvascsurg.org.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 4 Jordan et al 892.e1APPENDIX (online only). Collaborators and
institutions involved in the Aneurysm Treatment
using the Heli-FX Aortic Securement System Global
Registry (ANCHOR)
William D. Jordan, Jr.
Vascular Surgery and Endovascular Therapy e University of
Alabama, Birmingham, Ala
Jean Paul de Vries
Department of Vascular Surgery e St. Antonius Hospital,
Nieuwegein, The Netherlands
James Joye
Cardiovascular Disease e Heart & Vascular Institute, El
Camino Hospital, Mountain View, Calif
H.H. Eckstein
Department of Vascular Surgery e Clinic for Vascular and
Endovascular Surgery, Klinikum Rechts der Isar der
Technischen, Technical University Munich, Munich,
Germany
Joost van Herwaarden
Department of Vascular Surgery e University Medical
Center Utrecht, Utrecht, The Netherlands
Frank R. Arko
Vascular Surgery e Sanger Heart & Vascular Institute,
Carolinas Health Care System, Charlotte, NC
Paul Bove
Vascular and Endovascular Surgery e Peripheral Vascular
Diagnostic Center, William Beaumont, Royal Oak,
Mich
William Bohannon
Vascular Surgery e Scott & White Medical Center, Temple,
Tex
Bram Fioole
Department of Vascular Surgery e Maasstad Medical
Hospital, Rotterdam, The Netherlands
Carlo Setacci
Vascular and Endovascular Surgery Unit e University of
Siena, Siena, Italy
Timothy Resch
Department of Vascular Diseases e Malmö University
Hospital, Malmö, Sweden
Vicente Riambau
Angiology and Vascular Surgery e Thorax Institute
Hospital Clinic, Barcelona, Spain
Dierk Scheinert, Andrej Schmidt
Angiology and Vascular Surgery e Park Hospital, Leipzig,
Germany
Daniel Clair
Vascular Surgery e Cleveland Clinic, Cleveland, Ohio
Mohammed Moursi
Vascular Surgery e Central Arkansas Veterans Health
System, University of Arkansas for Medical Sciences, Little
Rock, Ark
Mark Farber
Vascular Surgery, School of Medicinee University of North
Carolina, Chapel Hill, NCJoerg Tessarek
Department of Vascular Surgery, Vascular Center e
St. Bonifatius Hospital, Lingen, Germany
Giovanni Torsello
Vascular Surgery e St. Franziskus-Hospital GmbH,
Münster, Germany
Mark Fillinger
Vascular Surgery, Geisel School of Medicine e Dartmouth-
Hitchcock Medical Center, Lebanon, NH
Marc Glickman
Vascular Surgery e Sentara Heart Hospital, Norfolk, Va
John Henretta
Vascular Surgery, Carolina Vascular eMission Hospital,
Asheville, NC
Kim Hodgson
Vascular Surgery Division, School of Medicine e Southern
Illinois University, Springﬁeld, Ill
Jeffrey Jim
Section of Vascular Surgery e Washington University School
of Medicine, St. Louis, Mo
Barry Katzen
Vascular and Interventional Radiology, Baptist Cardiac &
Vascular Institute e Baptist Hospital, Miami, Fla
Evan Lipsitz
Cardiovascular and Thoracic Surgery eMonteﬁore Medical
Center, Bronx, NY
Mitchell Cox
Vascular Surgery e Duke University Medical Center,
Durham, SC
Thomas Naslund
Division of Vascular Surgery e Vanderbilt University
Medical Center, Nashville, Tenn
Venkatesh Ramaiah
Vascular Surgery, Arizona Heart Institute e Abrazo
Health Care, Phoenix, Ariz
Marc Schermerhorn
Vascular and Endovascular Surgery e Beth Israel Deaconess
Medical Center, Boston, Mass
Peter Schneider
Vascular and Endovascular Surgery eHawaii Permanente
Medical Group, Honolulu, Hawaii
Benjamin Ware Starnes
Vascular Surgery Division e Harborview University of
Washington Medical Center, Seattle, Wash
Carlos Donayre
Vascular and Endovascular Surgerye Harbor-UCLA
Medical Center, Torrance, Calif
Manish Mehta
Vascular Surgery, Albany Vascular Group e The Institute
for Vascular Health and Disease, Albany, NY
Burkhart Zipfel
Department of Cardiothoracic and Vascular Surgery e
Deutsches Herzzentrum, Berlin, Germany
Nitin Malhotra
Vascular SurgeryeMichigan Vascular Center, Flint, Mich
David Varnagy
Vascular Surgery e Florida Hospital, Orlando, Fla
JOURNAL OF VASCULAR SURGERY
892.e2 Jordan et al October 2014William Moore, Jr.
Vascular Disease e Lexington Medical Center, West
Columbia, SC
Nick Cheshire, Colin Bicknell
Vascular Surgerye Imperial College, London, UK
Martin Back
Vascular Surgery, Florida Hospital e University of South
Florida, Tampa, Fla
Bart Muhs
Vascular and Endovascular Surgery e Yale School of
Medicine, New Haven, Conn
Mahmoud B. Malas
Endovascular Surgery, Heart and Vascular Institute e
Johns Hopkins, Baltimore, MdSyed Hussain
Vascular Surgery, OSF Saint Francis Medical Center e
HeartCare Peoria, Peoria, Ill
NavYash Gupta
Vascular Surgery e NorthShore University, Skokie, Ill
Dittmar Bockler
Department of Vascular Surgery e University of Heidelberg,
Heidelberg, Germany
Eric Verhoeven
Vascular and Endovascular Surgery e Klinikum
Nuremberg, Nuremberg, Germany
Michel Reijnen
Vascular Surgerye Rijnstate Hospital, Arnhem, The
Netherlands
